Unicycive Therapeutics
UNCY
28 hedge funds and large institutions have $19.1M invested in Unicycive Therapeutics in 2024 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 10 increasing their positions, 0 reducing their positions, and 7 closing their positions.
100% more capital invested
Capital invested by funds: $9.52M → $19.1M (+$9.56M)
71% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 7
22% more funds holding
Funds holding: 23 → 28 (+5)
0.09% less ownership
Funds ownership: 5.05% → 4.96% (-0.09%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$3.44M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
+$3.44M |
| 3 |
Walleye Capital
New York
|
+$2.01M |
| 4 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$1.61M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$904K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$1.32M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$1.1M |
| 3 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
-$787K |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$501K |
| 5 |
Renaissance Technologies
New York
|
-$16.6K |
UNCY Hedge Fund Activity: Q3 2024 in Review
28 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Unicycive Therapeutics (UNCY) for Q3 2024, worth a combined $19.1M — up 100% from $9.52M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new UNCY positions and 7 closed out — a net gain of 5 holders — while 10 added to existing stakes and 0 trimmed.
The largest buyer was Great Point Partners, opening a new position worth an estimated $3.44M. The largest seller was RA Capital Management, exiting entirely with an estimated $1.32M sold.
- 28 institutional investors held Unicycive Therapeutics (UNCY) as of Q3 2024, up from 23 in Q2 2024.
- Funds reported $19.1M of Unicycive Therapeutics stock for Q3 2024, up 100% quarter-over-quarter.
- 12 funds opened new Unicycive Therapeutics positions in Q3 2024 and 7 closed out, a net change of +5 holders.
- The largest Unicycive Therapeutics buyer in Q3 2024 was Great Point Partners, an estimated $3.44M added.
- The largest Unicycive Therapeutics seller in Q3 2024 was RA Capital Management, an estimated $1.32M sold.
Based on aggregated 13F filings for Q3 2024.